Fact checked byHeather Biele

Read more

April 19, 2023
1 min read
Save

Top news in Parkinson’s disease: Adjunctive opicapone, FDA seeks info on pump and more

Fact checked byHeather Biele
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Healio’s top stories on Parkinson’s disease in the first portion of 2023 include an FDA inquiry into a treatment pump, adjunctive therapy for carbidopa/levodopa and results from several clinical trials. Here’s what you may have missed:

FDA asks AbbVie for more information on Parkinson’s treatment pump

The FDA issued a complete response letter to AbbVie regarding its new drug application for ABBV-951 for the treatment of motor fluctuations in adults with advanced PD, seeking more information about the pump used for subcutaneous delivery. Read more.

Source: Adobe Stock.
Healio brings you the top Parkinson’s disease-related stories so far in 2023. Image: Adobe Stock

Adjunctive opicapone helps prolong plasma levodopa levels in patients with Parkinson’s

Adding once-daily opicapone 50 mg to carbidopa/levodopa therapy helped achieve and maintain plasma concentrations of levodopa in patients with PD. Read more.

Low use of new neurologic medications driven by relatively high cost

Despite production of new medications for a range of neurologic diseases, limited utilization is driven by high cost and similar efficacy to less expensive drugs. Read more.

Positive phase 2 results reported for novel combination therapy for Parkinson’s disease

CuraSen Therapeutics Inc. announced positive data from its randomized, double-blind crossover phase 2 study of combination clenbuterol/nadolol which improved cognition and mood in PD. Read more.

Topline results announced from phase 2 trial of treatment for early Parkinson’s disease

Neuraly announced its investigational glucagon-like peptide-1 receptor agonist did not meet the primary study endpoint of improvement in motor symptoms in patients with early, untreated PD, despite a favorable safety profile. Read more.